trending Market Intelligence /marketintelligence/en/news-insights/trending/Rk6uLYZOgxzfL8VhLaP8pw2 content esgSubNav
In This List

China plans to create adjuvant drug list, limit sales

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


China plans to create adjuvant drug list, limit sales

China's National Health Commission is planning to create a national adjuvant drug list combined with regulatory guidelines to curb their use, according to a notice by the regulator.

Adjuvant drugs are treatments applied to initial therapies as supplements. The state regulator will outline a national adjuvant drug list after provincial governments submit their lists of the top 20 best sold adjuvant drugs in their regions. The provincial regulators are asked to submit their lists by Dec. 31.

Provincial governments will also come up with their own list of adjuvant drugs within 10 workdays after the state regulator unveils the national list.

The state health regulator also plans to amend the national list more than once every year.

The state regulator said in the notice that tightening regulations on the use of adjuvant drugs is necessary to curb growing medical expenses at public hospitals.